header image

Take a look through our annual reports.

How to contact us for media/press enquiries.

Have a comment or question? Get in touch.


Octapharma USA Grant Funds First National Camp Exchange Program for Bleeding Disorders Community Camps


HOBOKEN, N.J. (July 13, 2017) – Octapharma USA has provided a grant to fund the first National Camp Exchange (NCE) for the bleeding disorders community, an adjunct program of the North American Camping Conference of Hemophilia...

Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with Von Willebrand disease (VWD) and haemophilia A


Lachen, Switzerland, July 11th 2017: Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors...

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A


Lachen, Switzerland, July 10th 2017: Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress,...

Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany


Lachen, Switzerland, July 6th, 2017 – Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress...

Octapharma USA Appoints Senior Biopharmaceutical Executive Richard E. Walters, Jr. as Vice President of Commercial Development


HOBOKEN, N.J. (June 5, 2017) – Octapharma USA has appointed Richard E. Walters, Jr. as Vice President of Commercial Development, assuming immediate responsibility for all U.S. product marketing, commercial development and...

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®


Lachen, Switzerland, May 22nd 2017: Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to...

FDA Grants Octapharma USA Orphan Drug Designation for Octagam® 10% for the Treatment of Dermatomyositis


HOBOKEN, N.J. (May 17, 2017) – The U.S. Food and Drug Administration (FDA) has granted Octapharma USA orphan drug designation for Octagam® Immune Globulin Intravenous (Human) 10% Liquid for the treatment of dermatomyositis, a...

Page 1 Page 2 next